{
  "hypotheses": [
    {
      "id": "H1",
      "prediction": "IF primary human hepatocytes are stratified by baseline GSH/GSSG ratio into tertiles (low <30, mid 30-60, high >60), THEN low-tertile cells treated with CBD (10 \u00b5M, 48h) will show \u22652.5-fold greater LDH release and \u22653-fold greater ALT leakage compared to high-tertile cells, with AUC for GSH/GSSG predicting >20% cell death of 0.65-0.75.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "CBD_concentration",
          "unit": "\u00b5M",
          "low": 1.0,
          "high": 50.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "LDH_release_fold",
          "unit": "fold-change",
          "low": 1.0,
          "high": 8.0,
          "distribution": "log-normal",
          "mean": null,
          "std": null
        },
        {
          "name": "cell_death_threshold",
          "unit": "%",
          "low": 15.0,
          "high": 30.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "AUC_ROC",
          "unit": "(normal,",
          "low": 0.5,
          "high": 0.9,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 8.0,
      "experimental_protocol": "Obtain cryopreserved primary human hepatocytes from \u226520 donors (BioIVT/Lonza). Measure baseline GSH/GSSG (enzymatic recycling assay). Treat with CBD (1, 5, 10, 25, 50 \u00b5M) \u00b1 valproate (300 \u00b5M) for 24/48/72h.",
      "expected_outcome": "Monotonic inverse relationship between baseline GSH/GSSG and hepatocyte death; ROC AUC 0.65-0.75; ketoconazole partially but not fully rescues toxicity in low-GSH donors, confirming dual mechanism.",
      "null_outcome": "No correlation between GSH/GSSG and cell death (AUC <0.55), or ketoconazole fully rescues toxicity (implicating CYP450 only, not VDAC-mediated oxidative stress).",
      "dose_ranges": {
        "CBD": {
          "doses": [
            1.0,
            5.0,
            10.0,
            25.0,
            50.0
          ],
          "unit": "\u00b5M;"
        },
        "Valproate": {
          "doses": [
            100.0,
            300.0,
            600.0
          ],
          "unit": "\u00b5M;"
        },
        "Ketoconazole": {
          "doses": [
            5.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "LDH release (CytoTox96)",
        "ALT (kinetic assay)",
        "GSH/GSSG (Cayman kit)",
        "ROS (CM-H2DCFDA)",
        "MMP (TMRM)",
        "VDAC1 oligomerization (DSP crosslinking + Western blot)",
        "CYP3A4 activity (P450-Glo)"
      ],
      "controls": [
        "Vehicle (0.1% DMSO)",
        "N-acetylcysteine (5 mM",
        "GSH rescue)",
        "VDAC1 inhibitor DIDS (100 \u00b5M",
        "VDAC-block control)",
        "ketoconazole alone",
        "heat-killed cells (LDH max)",
        "---",
        "##"
      ]
    },
    {
      "id": "H2",
      "prediction": "IF VDAC1 is knocked down (siRNA, >70% reduction) in HepG2 cells, THEN CBD-induced (10 \u00b5M, 48h) ROS production will decrease by \u226540% and cell death by \u226550%, whereas CYP3A4 activity inhibition by CBD will remain unchanged (\u00b110%).",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "VDAC1_knockdown_efficiency",
          "unit": "%",
          "low": 60.0,
          "high": 90.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "ROS_reduction",
          "unit": "%",
          "low": 20.0,
          "high": 70.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "cell_death_reduction",
          "unit": "%",
          "low": 25.0,
          "high": 75.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CBD_IC50_shift",
          "unit": "fold",
          "low": 1.0,
          "high": 3.0,
          "distribution": "log-normal",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 9.0,
      "experimental_protocol": "Transfect HepG2 cells with VDAC1 siRNA (3 sequences) or scrambled control (48h knockdown confirmed by qPCR/Western). Treat with CBD (1, 5, 10, 25 \u00b5M) for 24/48h. Parallel VDAC1-overexpression arm (pcDNA3-VDAC1). Measure all",
      "expected_outcome": "VDAC1 KD significantly reduces ROS and cell death without altering CYP3A4 inhibition by CBD; VDAC1 overexpression sensitizes cells. VDAC2 KD shows smaller or no effect. This mechanistically separates VDAC-mediated oxidative toxicity from CYP-mediated metabolic toxicity.",
      "null_outcome": "VDAC1 KD does not reduce CBD toxicity (\u226415% change), or VDAC1 KD also reduces CYP3A4 inhibition proportionally (suggesting confounded pathway, not independent mechanism).",
      "dose_ranges": {
        "CBD": {
          "doses": [
            1.0,
            5.0,
            10.0,
            25.0
          ],
          "unit": "\u00b5M;"
        }
      },
      "readouts": [
        "MitoSOX (mitochondrial superoxide)",
        "CM-H2DCFDA (total ROS)",
        "Annexin V/PI (apoptosis)",
        "CytoTox-Glo (cell death)",
        "CYP3A4 (P450-Glo)",
        "VDAC1 protein (Western)",
        "cytochrome c release (ELISA)",
        "caspase 3/7 (Caspase-Glo)"
      ],
      "controls": [
        "Scrambled siRNA + vehicle",
        "scrambled siRNA + CBD",
        "VDAC1 siRNA + vehicle",
        "NAC (5 mM) rescue",
        "DIDS (100 \u00b5M)",
        "erastin as VDAC-opening positive control",
        "---",
        "##"
      ]
    },
    {
      "id": "H3",
      "prediction": "IF hepatocytes are exposed to escalating doses of CBD or erastin, THEN the three-component panel (GSH, ATP/ADP, MMP) will show coordinated dose-dependent deterioration with \u22650.85 Spearman correlation between composite panel score and subsequent cell death (measured 24h later), and the panel at 6h will predict 48h toxicity with AUC \u22650.80.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "GSH_EC50_depletion",
          "unit": "\u00b5M",
          "low": 3.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "ATP_ADP_ratio_baseline",
          "unit": "(normal,",
          "low": 4.0,
          "high": 12.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "ATP_ADP_ratio_at_toxic_dose",
          "unit": "(normal,",
          "low": 0.5,
          "high": 3.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "MMP_reduction_at_EC50",
          "unit": "%",
          "low": 30.0,
          "high": 60.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "panel_AUC_for_48h_death",
          "unit": "(normal,",
          "low": 0.6,
          "high": 0.95,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "Spearman_rho",
          "unit": "(normal,",
          "low": 0.6,
          "high": 0.95,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 7.0,
      "experimental_protocol": "Use primary human hepatocytes (\u226510 donors) and HepaRG cells. Treat with CBD (1-50 \u00b5M) or erastin (1-20 \u00b5M) or acetaminophen (1-20 mM). Measure panel at 2, 6, 12, 24h. Measure cell death at 24, 48, 72h. Build composite score (weighted PCA of 3 metrics). Test whether 6h panel predicts 48h death. Include TRPV1 agonist capsaicin (10 \u00b5M) and TRPV1 antagonist AMG9810 (3 \u00b5M) + CBD arm to test confounding by non-mitochondrial CBD targets. Timeline: 10 weeks.",
      "expected_outcome": "All three panel components deteriorate",
      "null_outcome": "Panel components change non-concordantly or show poor predictive power (AUC <0.65); or capsaicin alone significantly alters panel metrics, indicating TRPV1-mediated confounding that undermines diagnostic specificity.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            1.0,
            5.0,
            10.0,
            25.0,
            50.0
          ],
          "unit": "\u00b5M;"
        },
        "Erastin": {
          "doses": [
            1.0,
            2.0,
            5.0,
            10.0,
            20.0
          ],
          "unit": "\u00b5M;"
        },
        "Acetaminophen": {
          "doses": [
            1.0,
            5.0,
            10.0,
            15.0,
            20.0
          ],
          "unit": "mM;"
        },
        "Capsaicin": {
          "doses": [
            10.0
          ],
          "unit": "\u00b5M;"
        },
        "AMG9810": {
          "doses": [
            3.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "GSH/GSSG (ThiolTracker + enzymatic)",
        "ATP/ADP (ADP/ATP Ratio Assay Kit",
        "Sigma)",
        "MMP (TMRM 50 nM",
        "live imaging + plate reader)",
        "cell death (LDH + Annexin V/PI)",
        "high-content imaging (Operetta/ImageXpress for single-cell MMP)"
      ],
      "controls": [
        "Vehicle (0.1% DMSO)",
        "FCCP (10 \u00b5M",
        "complete MMP collapse positive control)",
        "oligomycin (1 \u00b5M",
        "ATP synthase inhibition)",
        "NAC (5 mM",
        "GSH rescue)",
        "rotenone (1 \u00b5M",
        "Complex I inhibition as non-VDAC mitochondrial toxicant)",
        "---",
        "##"
      ]
    },
    {
      "id": "H4",
      "prediction": "IF a panel of cancer cell lines (n\u226515) is ranked by VDAC1 protein expression, THEN VDAC1-high lines (top quartile) will show \u22653-fold lower IC50 for erastin and \u22652-fold lower IC50 for CBD compared to VDAC1-low lines (bottom quartile), with VDAC1 expression explaining \u226530% of variance in drug sensitivity (R\u00b2 \u22650.30).",
      "source_claims": [],
      "key_variables": [],
      "parameters": [],
      "testability_score": 5.0,
      "experimental_protocol": "",
      "expected_outcome": "",
      "null_outcome": "",
      "dose_ranges": {},
      "readouts": [],
      "controls": []
    }
  ],
  "n_hypotheses": 4,
  "total_calls": 1,
  "latency_s": 55.01
}